Allstate Corp Acquires New Holdings in Hologic, Inc. (NASDAQ:HOLX)

Allstate Corp bought a new position in shares of Hologic, Inc. (NASDAQ:HOLX) during the fourth quarter, Holdings Channel reports. The fund bought 7,134 shares of the medical equipment provider’s stock, valued at approximately $514,000.

Several other institutional investors and hedge funds have also bought and sold shares of HOLX. Benson Investment Management Company Inc. purchased a new stake in shares of Hologic in the fourth quarter worth $4,832,000. Principal Financial Group Inc. raised its holdings in shares of Hologic by 0.6% in the 4th quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider’s stock valued at $19,547,000 after acquiring an additional 1,606 shares in the last quarter. Clean Yield Group boosted its position in shares of Hologic by 18.9% during the 4th quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock valued at $3,291,000 after acquiring an additional 7,266 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of Hologic by 2.9% during the third quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock worth $2,344,000 after purchasing an additional 800 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Hologic by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock worth $110,700,000 after purchasing an additional 238,222 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on HOLX. Royal Bank of Canada cut their price target on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a research note on Thursday, February 6th. Leerink Partnrs lowered shares of Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. William Blair restated an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Evercore ISI dropped their price target on Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research note on Thursday, February 6th. Finally, Needham & Company LLC lowered Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective on the stock. in a research report on Monday, February 3rd. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Trading Down 0.6 %

HOLX opened at $61.38 on Wednesday. Hologic, Inc. has a one year low of $60.34 and a one year high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The business has a 50 day simple moving average of $64.90 and a two-hundred day simple moving average of $72.97. The firm has a market capitalization of $13.77 billion, a price-to-earnings ratio of 19.36, a PEG ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.